Shares of Mersana Therapeutics Inc (MRSN) are trading -4% lower at a price of $7.285 at the time of this writing. While it's generally been a slightly dispirited day for this part of the market, the company is underperforming it's peers in the Health Care sector.


Mersana Therapeutics Inc has been trading between a 52-week high of $14.8 and a 52-week low of $2.68. The stock has a market cap of $708 Million.

Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana's lead product candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b and is in the expansion portion of a Phase 1 proof-of-concept clinical study in patients with ovarian cancer and NSCLC adenocarcinoma. XMT-1592, Mersana's second ADC product candidate targeting NaPi2b-expressing tumors, was created using Mersana's customizable and homogeneous Dolasynthen platform and is in the dose escalation portion of a Phase 1 proof-of-concept clinical study.

Mersana Therapeutics: Savvy Partnering But Further Progress Is Needed (NASDAQ:MRSN)
Seeking Alpha 08-15-22

Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
Benzinga 08-09-22

Mersana, GSK Ink $1.36B Biobuck Deal For Cancer-Focused Therapy
Benzinga 08-09-22

Recap: Mersana Therapeutics Q2 Earnings
Benzinga 08-08-22

Mersana Therapeutics, Inc. 2022 Q2 - Results - Earnings Call Presentation (NASDAQ:MRSN)
Seeking Alpha 08-08-22